GlassScriptPhysician profile
Tooba Mohammad
NPI 1265953970
$2,986.64
in general payments reported to CMS, 2019-2025
38 companies · $970 in 2025
The $970 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $443 · 2020: $147 · 2021: $502 · 2022: $261 · 2023: $169 · 2024: $494 · 2025: $970.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,524 · Education: $99.99 · Travel and Lodging: $9.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,523.71 |
| Education | $99.99 |
| Travel and Lodging | $9.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $570.76 | 2021-2023 | Vistaseal |
| Ethicon US, LLC | $567.44 | 2019-2022 | |
| Solventum Corporation | $195.88 | 2024-2025 | Prevena, 3m Duraprep Surgical, Prevena Restor Bellaform |
| Leica Microsystems INC. | $191.00 | 2024 | |
| Daiichi Sankyo INC. | $140.58 | 2025 | Datroway, Enhertu |
| Endomagnetics LTD | $135.91 | 2024 | Magtrace, Magseed |
| E.R. Squibb & Sons, L.L.C. | $115.00 | 2019 | |
| Seagen INC. | $99.99 | 2025 | |
| Merck Sharp & Dohme LLC | $93.72 | 2020-2025 | Keytruda, Welireg, Lynparza |
| Bayer Healthcare Pharmaceuticals INC. | $75.43 | 2025 | |
| Karyopharm Therapeutics INC. | $64.23 | 2025 | Xpovio |
| Sobi, INC | $61.73 | 2025 | |
| Incyte Corporation | $60.54 | 2025 | Jakafi, Monjuvi, Zynyz |
| Novartis Pharmaceuticals Corporation | $57.85 | 2025 | |
| Coherus Oncology, INC. | $46.38 | 2025 | Loqtorzi |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $41.31 | 2023-2025 | Calquence, Andexxa |
| Davol INC. | $39.43 | 2020 | |
| Hologic Sales and Service, LLC | $37.44 | 2025 | Sentimag, Localizer, Magtrace |
| Beone Medicines USA, INC. | $30.88 | 2025 | Brukinsa |
| Genmab U.S., INC. | $30.47 | 2025 | Tivdak |
| Elucent Medical | $28.66 | 2025 | |
| Kerecis Limited | $27.06 | 2020 | |
| Janssen Pharmaceuticals, INC | $25.69 | 2022 | |
| Avyxa Pharma, LLC | $24.45 | 2025 | |
| Integra Lifesciences Corporation | $21.84 | 2022 | |
| Puma Biotechnology, INC. | $21.41 | 2025 | |
| Emd Serono, INC. | $19.79 | 2025 | |
| Inogen, INC. | $18.29 | 2025 | |
| Stemline Therapeutics INC. | $18.13 | 2025 | Orserdu |
| Bioventus LLC | $17.17 | 2022 | |
| Boston Scientific Corporation | $15.60 | 2021 | |
| Kci USA, INC. | $15.60 | 2023 | Prevena, V.A.C. Veraflo Cleanse Choice |
| Novo Nordisk INC | $14.59 | 2019 | |
| Allergan, INC. | $13.68 | 2019 | |
| Depuy Synthes Sales INC. | $13.00 | 2022 | |
| Hydrofera LLC | $12.93 | 2022 | |
| Portola Pharmaceuticals, LLC | $12.40 | 2020 | |
| Lemaitre Vascular, INC. | $10.38 | 2023 | Artegraft Vascular Graft |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tooba Mohammad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.